Welcome to our dedicated page for Evoke Pharma SEC filings (Ticker: EVOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the cash-runway details, FDA milestones, and dilution risks buried in Evoke Pharma’s SEC documents can feel like deciphering medical jargon. When every update on GIMOTI—the company’s intranasal treatment for diabetic gastroparesis—may swing valuation, missing a footnote in a 300-page filing is costly.
Stock Titan solves this problem. Our AI reads every Evoke Pharma annual report 10-K simplified, scans each quarterly earnings report 10-Q filing, and flags material events in Evoke Pharma 8-K material events explained—all within minutes of hitting EDGAR. Interactive summaries translate clinical trial data, commercial-partner agreements, and royalty obligations into plain language, so you can understand Evoke Pharma SEC documents with AI instead of sifting through appendices.
Need real-time insights? Set alerts for Evoke Pharma Form 4 insider transactions real-time to watch executive stock transactions Form 4 and gauge management sentiment. Compare R&D spend trends with our Evoke Pharma earnings report filing analysis, or review how the proxy statement executive compensation aligns with shareholder dilution plans. Every filing type—from shelf registrations to Section 16 forms—is indexed and cross-linked:
- 10-K – liquidity outlook, FDA risk factors, patent life
- 10-Q – quarter-over-quarter trial expenses, revenue from GIMOTI
- 8-K – license deals, equity offerings, clinical data releases
- Forms 3, 4, 5 – Evoke Pharma insider trading Form 4 transactions history
- DEF 14A – Evoke Pharma proxy statement executive compensation details
Whether you’re modelling future capital needs or tracking Evoke Pharma quarterly earnings report 10-Q filing disclosures, our platform transforms dense biotech filings into clear, actionable insights—so you spend time analysing, not searching.
Evoke Pharma announced a planned cash tender offer by QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC, to acquire all outstanding shares of Evoke Pharma common stock. The transaction would proceed under an Agreement and Plan of Merger dated November 3, 2025.
The tender offer has not yet commenced. The buyer will file a Schedule TO with an offer to purchase and related documents, and Evoke Pharma will file a Schedule 14D-9. Investors are urged to read these materials carefully when available on the SEC’s website, as they will include the terms and conditions of the offer.
Evoke Pharma signed a definitive Agreement and Plan of Merger under which QOL Medical will launch a tender offer to acquire all outstanding shares for $11.00 in cash per share, subject to customary conditions. The Board unanimously approved the deal and recommends stockholders tender their shares.
The offer will be open for at least 20 business days and requires more than 50% of outstanding shares (with certain exercised options/warrants counted) to meet the minimum condition. Support agreements cover approximately 10.4% of outstanding shares. Following completion, Evoke will merge into a QOL subsidiary under DGCL 251(h), become wholly owned by QOL, and cease to be publicly traded.
The agreement includes standard terms, an outside date of May 3, 2026, and a $1.5 million termination fee under specified circumstances. An Eversana letter agreement provides for payment of $1.0 million of outstanding Cumulative Deferred Costs and loan principal and interest following a change of control or CSA expiration. Equity awards will be cashed out as described, and out‑of‑the‑money warrants receive no consideration unless Black Scholes value is elected.
Morgan Stanley and its affiliate Morgan Stanley Smith Barney LLC report beneficial ownership of 163,718 shares of Evoke Pharma Inc. common stock, representing 10.5% of the class. The filing shows no sole voting or dispositive power and shared dispositive power of 163,718 shares, indicating holdings reported on behalf of Morgan Stanley reporting units. The filing is submitted on a Schedule 13G basis and includes exhibits for a joint filing agreement and subsidiary identification.
Evoke Pharma reported continued commercial progress for Gimoti with accelerating product sales but persistent operating losses and a constrained cash runway. Net product sales were $3,752,142 for the quarter and $6,832,300 for the six months ended June 30, 2025. The company recorded a net loss of $1,570,976 for the quarter and $2,877,154 for the six-month period, reducing stockholders' equity to $4,374,492 and an accumulated deficit of $131,668,786. Cash and cash equivalents totaled $12,059,072 at period end.
The company has a $5.0 million note payable and accrued interest bringing the loan balance to $7.4 million as of June 30, 2025, and reports approximately $79.8 million of unreimbursed commercialization costs to its commercial partner, Eversana. Management discloses substantial doubt about the ability to continue as a going concern and expects current cash and forecasted net sales to fund operations into the third quarter of 2026 under the current plan.
FAQ
What is the current stock price of Evoke Pharma (EVOK)?
What is the market cap of Evoke Pharma (EVOK)?
